logo

For the Inventor, By the Inventor

Chandler, AZ, United States of America

Chris Diehnelt

This inventor holds 8 USPTO granted patents and 1 published patent application. Top assignee: Arizona State University. Active years: 2016-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chris Diehnelt. Retrieved from https://idiyas.com/inventor/chris-diehnelt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 62.5

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 37(Granted Patents)


Company Filing History:

goldMedal8 out of 2,159 
 
Arizona State University
 patents

Years Active: 2016-2023

Loading Chart...
8 patents (USPTO):Explore Patents
1. 11789029 - Temporal traumatic brain injury biomarkers and methods of use thereof (2023-10-17),
2. 11752195 - Compositions and methods of use of synthetic peptides withinhibitory activity (2023-09-12),
3. 11125743 - Detection of norovirus using norovirus-specific toehold switches (2021-09-21),
4. 10125167 - Compositions and methods for treating MRSA infections and for sensitizing MRSA to beta-lactam antibiotics (2018-11-13),
5. 9766239 - Synbodies for detection of human norovirus (2017-09-19),
6. 9757472 - [object Object] (2017-09-12),
7. 9482666 - High throughput selection of specific cell binding and lytic polypeptides (2016-11-01),
8. 9309298 - Anti-bacterial polypeptides and pathogen specific synthetic antibodies (2016-04-12),

Title: Innovations and Contributions of Inventor Chris Diehnelt

Introduction

Chris Diehnelt is a prominent inventor based in Chandler, AZ, known for his significant contributions to the field of biomedical research. With a total of eight patents to his name, Diehnelt has made remarkable strides in the discovery and application of biomarkers and antimicrobial peptides.

Latest Patents

Diehnelt's latest patents include groundbreaking work on temporal traumatic brain injury biomarkers and methods of use thereof. This innovative pipeline employs domain antibody phage display, next-generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics. The patents disclose temporal biomarkers of traumatic brain injury, which include synthetic peptides comprising HCDR3 sequences identified through the disclosed pipeline. These synthetic peptides typically contain fewer than 30 amino acid residues and are linked to a biotin scaffold. Another notable patent involves synthetic antimicrobial peptides, which are designed to modulate symptoms of infections caused by pathogens such as mycobacteria and methicillin-resistant Staphylococcus aureus (MRSA). The methods outlined in this patent also include identifying synthetic antimicrobial peptides against pathogens with no known effective treatment.

Career Highlights

Diehnelt is affiliated with Arizona State University, where he continues to advance his research and innovation in the biomedical field. His work has garnered attention for its potential applications in medical diagnostics and treatment.

Collaborations

Diehnelt collaborates with esteemed colleagues, including Stephen Albert Johnston and Valeriy Domenyuk, to further enhance the impact of his research.

Conclusion

Chris Diehnelt's contributions to the field of biomedical research through his patents and collaborations highlight his role as an influential inventor. His work on biomarkers and antimicrobial peptides has the potential to significantly impact medical science and patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…